

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*

SERIAL NUMBER: 09/903,216

EXAMINER: Karen A. Canella

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS

November 1, 2002  
Boston, Massachusetts

Commissioner for Patents  
Washington, D.C. 20231



# 9/B  
FM  
4/7/02

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

***In the Claims:***

Cancel claim 37.

**REMARKS**

Claims 16-22 and 39-56 are pending. Claim 37 was canceled as being drawn to the non-elected invention. No new matter has been added by this amendment.

**CONCLUSION**

On the basis of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21486-032DIV2.

Respectfully submitted,

**RECEIVED**  
NOV 05 2002  
TECH CENTER 1600/2900

Ingrid Beattie  
Ingrid Beattie, Reg. No. 42,306  
Attorney for Applicants  
c/o MINTZ LEVIN COHN FERRIS  
GLOVSKY & POPEO, PC  
One Financial Center  
Boston, Massachusetts 02111  
Tel.: (617) 542 6000  
Fax: (617) 542-2241

Express Mail Label No.: EL862265543US  
Date of Deposit: November 1, 2001

Attorney Docket No. 21486-032DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Wands *et al.*


SERIAL NUMBER: 09/903,216

EXAMINER: Karen A. Canella

FILING DATE: July 11, 2001

ART UNIT: 1642

FOR: DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS



November 1, 2002  
Boston, Massachusetts

Commissioner for Patents  
Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Restriction Requirement (Paper 7) mailed on October 2, 2002, Applicants elect the invention of Group I (claims 16-22, and 39-56), drawn to a method of inhibiting tumor growth in a mammal comprising administering a compound which inhibits the enzymatic activity of HAAH. This election is made without traverse.

Applicant reserves the right to prosecute claims which are equal to or broader in scope in this, or future applications related to the above-identified patent application.

A response to the Office Action is due November 1, 2002. Although Applicant believes no fee is due in connection with this filing, the Commissioner is hereby authorized to charge any fee that may be due to Deposit Account No. 50-0311 (Reference No. 21486-032DIV2).

Respectfully submitted,

*IA Beattie*

Ingrid Beattie, Reg. No. 42,306

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY & POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 1724927v1

**RECEIVED**

NOV 05 2002

TECH CENTER 1600/2900

# 8  
JM  
11/1/02